Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma

Shreya J. Shetty, Lokesh Bathla, Venkatesh Govindarajan, Peter Thomas, Brian W. Loggie

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Diffuse malignant peritoneal mesothelioma is a rare, aggressive disease. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have improved outcomes where systemic chemotherapy has not succeeded. In this study, we compare outcomes of patients treated with mitomycin or carboplatin as perfusate. In this retrospective study, 47 procedures (CRS 1 HIPEC) were conducted on 44 patients between March 2003 and August 2010 with either mitomycin or carboplatin. x2 and Student's t test were used for comparison of clinicopathological variables and Kaplan-Meier curves and log rank test were used to compare overall survival.Median survival of themitomycin groupwas 18 months with 1- and 5-year survivals of 72.3 and 27.3 per cent, respectively. Median survival of the carboplatin group was not reached and 1- and 5-year survivals were 89.7 and 62.5 per cent, respectively (P 5 0.014).Mean hospital and intensive care unit length of stay was 18.9 and 8.7 days in the mitomycin group and 12.5 and 2.3 days in the carboplatin group (P 5 0.0069). Mean number of packed red blood cell units transfused was higher in the mitomycin group compared with the carboplatin group (3.54 vs 0.83, P <0.05). There was no postoperative mortality. HIPEC with carboplatin in diffuse malignant peritoneal mesothelioma is associated with improved overall survival and shorter hospital stay compared with HIPEC with mitomycin.

Original languageEnglish
Pages (from-to)348-352
Number of pages5
JournalAmerican Surgeon
Volume80
Issue number4
StatePublished - Apr 1 2014

Fingerprint

Carboplatin
Mitomycin
Drug Therapy
Survival
Length of Stay
Rare Diseases
Intensive Care Units
Malignant Mesothelioma
Retrospective Studies
Erythrocytes
Students
Mortality

All Science Journal Classification (ASJC) codes

  • Surgery
  • Medicine(all)

Cite this

Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma. / Shetty, Shreya J.; Bathla, Lokesh; Govindarajan, Venkatesh; Thomas, Peter; Loggie, Brian W.

In: American Surgeon, Vol. 80, No. 4, 01.04.2014, p. 348-352.

Research output: Contribution to journalArticle

@article{ed6c870b3f764e6e96d83ef2416a2801,
title = "Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma",
abstract = "Diffuse malignant peritoneal mesothelioma is a rare, aggressive disease. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have improved outcomes where systemic chemotherapy has not succeeded. In this study, we compare outcomes of patients treated with mitomycin or carboplatin as perfusate. In this retrospective study, 47 procedures (CRS 1 HIPEC) were conducted on 44 patients between March 2003 and August 2010 with either mitomycin or carboplatin. x2 and Student's t test were used for comparison of clinicopathological variables and Kaplan-Meier curves and log rank test were used to compare overall survival.Median survival of themitomycin groupwas 18 months with 1- and 5-year survivals of 72.3 and 27.3 per cent, respectively. Median survival of the carboplatin group was not reached and 1- and 5-year survivals were 89.7 and 62.5 per cent, respectively (P 5 0.014).Mean hospital and intensive care unit length of stay was 18.9 and 8.7 days in the mitomycin group and 12.5 and 2.3 days in the carboplatin group (P 5 0.0069). Mean number of packed red blood cell units transfused was higher in the mitomycin group compared with the carboplatin group (3.54 vs 0.83, P <0.05). There was no postoperative mortality. HIPEC with carboplatin in diffuse malignant peritoneal mesothelioma is associated with improved overall survival and shorter hospital stay compared with HIPEC with mitomycin.",
author = "Shetty, {Shreya J.} and Lokesh Bathla and Venkatesh Govindarajan and Peter Thomas and Loggie, {Brian W.}",
year = "2014",
month = "4",
day = "1",
language = "English",
volume = "80",
pages = "348--352",
journal = "American Surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "4",

}

TY - JOUR

T1 - Comparison of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma

AU - Shetty, Shreya J.

AU - Bathla, Lokesh

AU - Govindarajan, Venkatesh

AU - Thomas, Peter

AU - Loggie, Brian W.

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Diffuse malignant peritoneal mesothelioma is a rare, aggressive disease. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have improved outcomes where systemic chemotherapy has not succeeded. In this study, we compare outcomes of patients treated with mitomycin or carboplatin as perfusate. In this retrospective study, 47 procedures (CRS 1 HIPEC) were conducted on 44 patients between March 2003 and August 2010 with either mitomycin or carboplatin. x2 and Student's t test were used for comparison of clinicopathological variables and Kaplan-Meier curves and log rank test were used to compare overall survival.Median survival of themitomycin groupwas 18 months with 1- and 5-year survivals of 72.3 and 27.3 per cent, respectively. Median survival of the carboplatin group was not reached and 1- and 5-year survivals were 89.7 and 62.5 per cent, respectively (P 5 0.014).Mean hospital and intensive care unit length of stay was 18.9 and 8.7 days in the mitomycin group and 12.5 and 2.3 days in the carboplatin group (P 5 0.0069). Mean number of packed red blood cell units transfused was higher in the mitomycin group compared with the carboplatin group (3.54 vs 0.83, P <0.05). There was no postoperative mortality. HIPEC with carboplatin in diffuse malignant peritoneal mesothelioma is associated with improved overall survival and shorter hospital stay compared with HIPEC with mitomycin.

AB - Diffuse malignant peritoneal mesothelioma is a rare, aggressive disease. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have improved outcomes where systemic chemotherapy has not succeeded. In this study, we compare outcomes of patients treated with mitomycin or carboplatin as perfusate. In this retrospective study, 47 procedures (CRS 1 HIPEC) were conducted on 44 patients between March 2003 and August 2010 with either mitomycin or carboplatin. x2 and Student's t test were used for comparison of clinicopathological variables and Kaplan-Meier curves and log rank test were used to compare overall survival.Median survival of themitomycin groupwas 18 months with 1- and 5-year survivals of 72.3 and 27.3 per cent, respectively. Median survival of the carboplatin group was not reached and 1- and 5-year survivals were 89.7 and 62.5 per cent, respectively (P 5 0.014).Mean hospital and intensive care unit length of stay was 18.9 and 8.7 days in the mitomycin group and 12.5 and 2.3 days in the carboplatin group (P 5 0.0069). Mean number of packed red blood cell units transfused was higher in the mitomycin group compared with the carboplatin group (3.54 vs 0.83, P <0.05). There was no postoperative mortality. HIPEC with carboplatin in diffuse malignant peritoneal mesothelioma is associated with improved overall survival and shorter hospital stay compared with HIPEC with mitomycin.

UR - http://www.scopus.com/inward/record.url?scp=84904400697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904400697&partnerID=8YFLogxK

M3 - Article

VL - 80

SP - 348

EP - 352

JO - American Surgeon

JF - American Surgeon

SN - 0003-1348

IS - 4

ER -